Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,294 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00905047 | Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer(COLOCROSS) | completed | Phase 3 | 89 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 |
| clinicaltrials |
| NCT00217737 | Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | completed | Phase 3 | 2,431 | National Cancer Institute (NCI)NIH | 5 | Aug 25, 2026 | clinicaltrials |
| NCT01918527 | Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer | completed | Phase 3 | 250 | Vejle HospitalOTHER | 3 | Aug 21, 2026 | clinicaltrials |
| NCT00265850 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,334 | Alliance for Clinical Trials in OncologyOTHER | 2 | Aug 7, 2026 | clinicaltrials |
| NCT05198934 | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation(CodeBreak300) | completed | Phase 3 | 160 | AmgenINDUSTRY | 12 | Jul 22, 2026 | clinicaltrials |
| NCT03879109 | Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer(GRECCAR15) | completed | Phase 3 | 58 | University Hospital, BordeauxOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT00079274 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | completed | Phase 3 | 3,397 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05064059 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | completed | Phase 3 | 441 | Merck Sharp & Dohme LLCINDUSTRY | 21 | May 26, 2026 | clinicaltrials |
| NCT01150045 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery | completed | Phase 3 | 2,527 | Alliance for Clinical Trials in OncologyOTHER | 3 | May 19, 2026 | clinicaltrials |
| NCT02514278 | Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy(GRECCAR12) | completed | Phase 3 | 218 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04835142 | Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC | completed | Phase 3 | 688 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT02584985 | Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer(ETAP) | completed | Phase 3 | 226 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT00102011 | Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer(00-046) | completed | Phase 3 | 4,952 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02956876 | Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer(INCISIVE) | completed | Phase 3 | 207 | University Hospital, RouenOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT00208260 | Intensified Chemotherapy in CRC After Resection of Liver Metastases | completed | Phase 2 / Phase 3 | 124 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07320950 | Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients | completed | Phase 3 | 333 | Sun Yat-sen UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05600309 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | completed | Phase 3 | 94 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02967289 | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting(IROCAS) | completed | Phase 3 | 792 | UNICANCEROTHER | 2 | Nov 17, 2025 | clinicaltrials |
| NCT01999634 | Monitoring by Microdialysis of Postoperative Complications After Proctectomy(MTM-COLON-II) | completed | Phase 3 | 21 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT01727388 | Informativeness to Digital Rectal Examination(RIFIONA) | completed | Phase 3 | 320 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT02605265 | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1(CinClare) | completed | Phase 3 | 356 | Fudan UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04941300 | ColoRectal Cancer Screening for Southern California Community Health Centers | completed | Phase 3 | 55,999 | University of California, San DiegoOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT01804790 | Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer(Néofirinox) | completed | Phase 3 | 461 | UNICANCEROTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03206151 | CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | completed | Phase 3 | 520 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT02934529 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab(AIO-KRK-0114) | completed | Phase 3 | 673 | Ludwig-Maximilians - University of MunichOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer(FRESCO-2) | completed | Phase 3 | 691 | Hutchison Medipharma LimitedINDUSTRY | 14 | Apr 4, 2025 | clinicaltrials |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases(CAIRO5) | completed | Phase 3 | 530 | Dutch Colorectal Cancer GroupOTHER | 2 | Feb 6, 2025 | clinicaltrials |
| NCT01878422 | Sequential Treatment Strategy for Metastatic Colorectal Cancer(ITACa) | completed | Phase 3 | 376 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT03511963 | A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC | completed | Phase 3 | 677 | Shanghai Henlius BiotechINDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04456699 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | completed | Phase 3 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Oct 29, 2024 | clinicaltrials |
| NCT02494973 | Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases(PACHA-01) | completed | Phase 2 / Phase 3 | 104 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 28, 2024 | clinicaltrials |
| NCT02563002 | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | completed | Phase 3 | 307 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 3, 2024 | clinicaltrials |
| NCT04737187 | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients(SUNLIGHT) | completed | Phase 3 | 492 | Taiho Oncology, Inc.INDUSTRY | 14 | Sep 24, 2024 | clinicaltrials |
| NCT01607957 | Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(RECOURSE) | completed | Phase 3 | 800 | Taiho Oncology, Inc.INDUSTRY | 13 | Sep 19, 2024 | clinicaltrials |
| NCT00297791 | COLOR II: Laparoscopic Versus Open Rectal Cancer Removal(COLORII) | completed | Phase 3 | 1,044 | Nova Scotia Health AuthorityOTHER | 9 | Aug 21, 2024 | clinicaltrials |
| NCT03520946 | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients(RAMTAS) | completed | Phase 3 | 430 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03306394 | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).(PRECONNECT) | completed | Phase 3 | 907 | Institut de Recherches Internationales ServierOTHER | 16 | Jul 25, 2024 | clinicaltrials |
| NCT01345175 | Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer | completed | Phase 3 | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03781154 | Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors | completed | Phase 3 | 31 | University of Colorado, DenverOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT05726097 | Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure | completed | Phase 3 | 147 | Region SkaneOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05921942 | The Impact of Metformin Administration on the Clinical Outcome of Stage IV Colon Cancer | completed | Phase 3 | 70 | Ain Shams UniversityOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03414983 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread(CheckMate 9X8) | completed | Phase 2 / Phase 3 | 196 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 18, 2023 | clinicaltrials |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer(CanStem303C) | completed | Phase 3 | 1,253 | Sumitomo Pharma America, Inc.INDUSTRY | 16 | Nov 15, 2023 | clinicaltrials |
| NCT02394795 | Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC(PARADIGM) | completed | Phase 3 | 823 | TakedaINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials